207 related articles for article (PubMed ID: 22943457)
1. Successful treatment with the mTOR inhibitor everolimus in a patient with perivascular epithelioid cell tumor.
Gennatas C; Michalaki V; Kairi PV; Kondi-Paphiti A; Voros D
World J Surg Oncol; 2012 Sep; 10():181. PubMed ID: 22943457
[TBL] [Abstract][Full Text] [Related]
2. Extrarenal perivascular epithelioid cell tumors (PEComas) respond to mTOR inhibition: clinical and molecular correlates.
Dickson MA; Schwartz GK; Antonescu CR; Kwiatkowski DJ; Malinowska IA
Int J Cancer; 2013 Apr; 132(7):1711-7. PubMed ID: 22927055
[TBL] [Abstract][Full Text] [Related]
3. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors.
Wagner AJ; Malinowska-Kolodziej I; Morgan JA; Qin W; Fletcher CD; Vena N; Ligon AH; Antonescu CR; Ramaiya NH; Demetri GD; Kwiatkowski DJ; Maki RG
J Clin Oncol; 2010 Feb; 28(5):835-40. PubMed ID: 20048174
[TBL] [Abstract][Full Text] [Related]
4. Dramatic tumor response to everolimus for malignant epithelioid angiomyolipoma.
Shitara K; Yatabe Y; Mizota A; Sano T; Nimura Y; Muro K
Jpn J Clin Oncol; 2011 Jun; 41(6):814-6. PubMed ID: 21415002
[TBL] [Abstract][Full Text] [Related]
5. Effective Therapeutic Intervention and Comprehensive Genetic Analysis of mTOR Signaling in PEComa: A Case Report.
Weeber F; Koudijs MJ; Hoogstraat M; Besselink NJ; VAN Lieshout S; Nijman IJ; Cuppen E; Offerhaus GJ; Voest EE
Anticancer Res; 2015 Jun; 35(6):3399-403. PubMed ID: 26026101
[TBL] [Abstract][Full Text] [Related]
6. A rare metastatic mesenteric malignant PEComa with TSC2 mutation treated with palliative surgical resection and nab-sirolimus: a case report.
Meredith L; Chao T; Nevler A; Basu Mallick A; Singla RK; McCue PA; Bowne WB; Jiang W
Diagn Pathol; 2023 Apr; 18(1):45. PubMed ID: 37041531
[TBL] [Abstract][Full Text] [Related]
7. Dia-gnostic Challenges and Extraordinary Treatment Response in Rare Malignant PEComa Tumor of the Kidney.
Huľová S; Sycova-Mila Z; Macák D; Janega P; Chovanec M; Mardiak J; Mego M
Klin Onkol; 2018; 31(6):448-452. PubMed ID: 30545225
[TBL] [Abstract][Full Text] [Related]
8. RETROPERITONEAL PERIVASCULAR EPITHELIOID CELL NEOPLASM (PECOMA) RESPONSE TO MTOR KINASE INHIBITION. A CASE REPORT WITH LITERATURE REVIEW.
Damirov F; Menge F; Hohenberger P
Georgian Med News; 2022 Nov; (332):56-59. PubMed ID: 36701777
[TBL] [Abstract][Full Text] [Related]
9. Role of mammalian target of rapamycin inhibitor in the treatment of metastatic epithelioid angiomyolipoma: a case report.
Kohno J; Matsui Y; Yamasaki T; Shibasaki N; Kamba T; Yoshimura K; Sumiyoshi S; Mikami Y; Ogawa O
Int J Urol; 2013 Sep; 20(9):938-41. PubMed ID: 23347205
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Advanced Malignant Uterine Perivascular Epithelioid Cell Tumor with mTOR Inhibitors: Single-institution Experience and Review of the Literature.
Starbuck KD; Drake RD; Budd GT; Rose PG
Anticancer Res; 2016 Nov; 36(11):6161-6164. PubMed ID: 27793946
[TBL] [Abstract][Full Text] [Related]
11. Editorial comment to role of mammalian target of rapamycin inhibitor in the treatment of metastatic epithelioid angiomyolipoma: a case report.
Nagashima Y
Int J Urol; 2013 Sep; 20(9):942. PubMed ID: 23379352
[No Abstract] [Full Text] [Related]
12. First pancreatic perivascular epithelioid cell tumor (PEComa) treated by mTOR inhibitor.
Gondran H; Thebaud E; Moreau A; Le Rhun M; Touchefeu Y; Regenet N; Musquer N
Pancreatology; 2019 Jun; 19(4):566-568. PubMed ID: 31130397
[TBL] [Abstract][Full Text] [Related]
13. Clinical presentations and molecular studies of invasive renal epithelioid angiomyolipoma.
Chuang CK; Lin HCA; Tasi HY; Lee KH; Kao Y; Chuang FL; Chang YH; Lin PH; Liu CY; Pang ST
Int Urol Nephrol; 2017 Sep; 49(9):1527-1536. PubMed ID: 28547571
[TBL] [Abstract][Full Text] [Related]
14. Addition of Antiestrogen Treatment in Patients with Malignant PEComa Progressing to mTOR Inhibitors.
Sanfilippo R; Fabbroni C; Fucà G; Fumagalli E; Morosi C; Sbaraglia M; Gronchi A; Collini P; Dei Tos AP; Casali PG
Clin Cancer Res; 2020 Oct; 26(20):5534-5538. PubMed ID: 32605908
[TBL] [Abstract][Full Text] [Related]
15. Sirolimus and temsirolimus for epithelioid angiomyolipoma.
Wolff N; Kabbani W; Bradley T; Raj G; Watumull L; Brugarolas J
J Clin Oncol; 2010 Feb; 28(5):e65-8. PubMed ID: 20048172
[No Abstract] [Full Text] [Related]
16. Combination targeted therapy of VEGFR inhibitor, sorafenib, with an mTOR inhibitor, sirolimus induced a remakable response of rapid progressive Uterine PEComa.
Gao F; Huang C; Zhang Y; Sun R; Zhang Y; Wang H; Zhang S
Cancer Biol Ther; 2016 Jun; 17(6):595-8. PubMed ID: 27030639
[TBL] [Abstract][Full Text] [Related]
17. Malignant renal epithelioid angiomyolipoma with liver metastasis after resection: a case report with multimodality imaging and review of the literature.
Vicens RA; Jensen CT; Korivi BR; Bhosale PR
J Comput Assist Tomogr; 2014; 38(4):574-7. PubMed ID: 24887578
[TBL] [Abstract][Full Text] [Related]
18. Fluorine-18-FDG PET/CT in a patient with angiomyolipoma: Response to mammalian target of rapamycin inhibitor therapy.
Anwar H; Sachpekidis C; Schwarzbach M; Dimitrakopoulou-Strauss A
Hell J Nucl Med; 2017; 20(2):169-171. PubMed ID: 28697195
[TBL] [Abstract][Full Text] [Related]
19. Gynecologic perivascular epithelioid cell tumors (PEComas): a review of recent evidence.
Levin G; Capella MP; Meyer R; Brezinov Y; Gotlieb WH
Arch Gynecol Obstet; 2024 Jun; 309(6):2381-2386. PubMed ID: 38664269
[TBL] [Abstract][Full Text] [Related]
20. Malignant epithelioid angiomyolipoma: tumor and metabolic response to everolimus as evaluated with positron emission tomography.
Faria E; Turturro F; Rao P; Matin SF
Clin Genitourin Cancer; 2013 Dec; 11(4):e1-5. PubMed ID: 23791549
[No Abstract] [Full Text] [Related]
[Next] [New Search]
